Dr. Atsuo Yanagisawa President Japanese College of Intravenous Therapy International Society for Orthomolecular Medicine

Transcription

1 Intravenous Vitamin C Therapy In Japan Dr. Atsuo Yanagisawa President Japanese College of Intravenous Therapy International Society for Orthomolecular Medicine 1

2 Dr. Atsuo Yanagisawa, MD, PhD Director SPIC Salon Medical Clinic President Japanese college of Intravenous Therapy International Society for Orthomolecular Medicine Special interests Certified Chelation Therapy (ACAM, USA) Master of Intravenous Vitamin C Therapy (Japan) Fellow of American College of Cardiology (USA)

3 Dr. Atsuo Yanagisawa, MD, PhD Professorship Former Professor of Medicine & Cardiology Professor of Graduate School of Project Design Awarded 2011 Orthomolecular Medicine Hall of Fame (Canada) 2014 Award of Antoine Béchamp (France) 2014 Pearl Maker Award of Riordan Clinic (USA) Board President, Int l Congress of Integrative Medicine (2010) Board, International Society of Personalized Medicine Director, Int l Educational Center for Integrative Medicine

4 SPIC Salon Medical Clinic Kamakura City, Japan

5 Today s topics 1. Intravenous High-dose Vitamin C Therapy for Cancer Treatment in Japan 2. Nutrition supplements along with IVC for cancer patients 5

6 % survival % survival 生存率 Breast cancer Stage III & IV years Breast cancer years ago years

7

8 Intravenous Vitamin C Therapy for Cancer Treatment 8

9 Drs. Ewan Cameron & Linus Pauling <Subjects> : 100 patients with terminal cancer <Treatments>: i.v. Vitamin C 10 g/day for 10 days + oral Vitamin C 10g <Control subjects>: 1,000 patietns 1976 Volume 73: , 1976 <Results> : Survival period was 4.2 times longer in Vitamin C treated patients. <

10 Cameron E & and Pauling L: Volume 73: , 1976 % survival Terminal Caner Patients treated with iv & oral Vitamin C controls survival time 10

11 Colon Stomach Lung Breast Proc Natl Acad Sci USA 75: September, 1978

12 Kidney Rectum Bladder Ovary

13 1979 Creagan et al, N Engl J Med 301: 687, 1979 Moertel et al, N Engl J Med 312: 137, Mayo Clinic Studies Dr. Creagan and Moertel treated terminal cancer patients using only 2 months treatment of oral vitamin C without IVC and showed no benefit. The medical scientists lost interest about Vitamin C for cancer, but

14 2005 Volume 102: September 20, 2005 Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a prodrug to deliver hydrogen peroxide to tissues. Qi Chen*, Michael Graham Espey, Murali C. Krishna, James B. Mitchell, Christopher P. Corpe*, Garry R. Buettner, Emily Shacter, and Mark Levine* National Institute of Health National Cancer Institute Food & Drug Administration, U.S.A. 14

15 2005 Volume 102: September 20,

16 Copyright 2007 by the National Academy of Sciences 16

17 Fig. 5. Pharmacologic ascorbic acid concentrations: mechanisms for selective cell death Mechanism of Vitamin C-induced selective cancer cell death Copyright 2007 by the National Academy of Sciences

18 18

19 Clinical Trial of IVC for Cancer - 1 Lung Iowa University 2015, USA Stomac Sun Yat-sen University 2016, China Colon Jefferson University 2011, USA Sun Yat-sen University 2017, China Jefferson University 2009, USA Kansas University 2011, USA Pancreas CTA* in Philadelphia 2012, USA Bruckner Cancer Center 2014, USA Iowa University 2014,USA Liver Jefferson University 2012, USA Breast CTA* in Chicago 2016, USA Ovary Kansas University 2005, USA *CTA; Cancer Treatments for America

20 Clinical Trial of IVC for Cancer - 2 Prostate Copenhagen University 2010, Denmark John s Hopkins Universty 2015, USA Lymphoma Jefferson University 2008, USA Tokai University 2008, Japan Iowa University-phase , USA Brain Iowa University-phase , USA Neblaska University 2013, USA Safety McGill University 2008, Canada QOL JCIT 2010, Japan Chemo resistant -McGill University Terminal solid tumor CTA in Chicago 2010, Canada 2006, USA

21 High-Dose Parenteral Ascorbate Enhanced Chemo-sensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy ScienceTranslationalMedicine.org 2014; 6 : 222 Kansas University Medical Center National Institute of Health (USA) 21

22 Chemosensitizing effects of Vitamin C to carboplatin VC: Vitamin C Cp : Carboplatin VC Cp CP+VC 3.2mM 0.15mM ScienceTranslationalMedicine.org 2014; 6 :

23 Time to disease progression or relapse for each subject. (The bars represent median time) VC: Vitamin C Cp : Carboplatin Pax: paclitaxel ScienceTranslationalMedicine.org 2014; 6 : 222 VC (n = 10) 23

24 Reduction of toxicity in ovarian cancer patients after adding Vitamin C to chemotherapy VC (n = 13) VC: Vitamin C Cp : Carboplatin Pax: paclitaxel ScienceTranslationalMedicine.org 2014; 6 :

25 CONCLUSIONS (1) The combination of vitamin C with chemotherapeutic agents carboplatin and paclitaxel significantly inhibited ovarian cancer in mouse models. (2)Intravenous vitamin C reduced chemotherapy-associated adverse effects in patients with ovarian cancer. ScienceTranslationalMedicine.org 2014; 6 :

26 26

27

28 Effects of IVC in Pts with Glionlastoma

29 High Dose Intravenous Vitamin C improve Quality of Life in Cancer Patients. 29

30 Effects of High Dose Intravenous Vitamin C Therapy on Health-related Quality of Life in Cancer Patients. Methods Organization Participants Subjects QOL evaluation Administration of IVC Japanese College of IV Therapy 140 clinics and 5 hospitals 60 Cancer pts who had no history of IVC EORTC QLQ-C30 <Riordan IVC Protocol> Patients were administered IVC twice a week. 30

31 Vitamin C (A.A.) # Grams (# cc) Riordan IVC Standard Infusion Protocol Developed and Typically Used at Center Diluent Type MgCl Added Infusion Time (~0.5 gram/minute) Osmolality (calculated) 15 grams (30cc) 250cc Ringer's Lactate 1cc ~30 minutes* 827 mosm/l 25 grams (50cc) 250cc Sterile Water 1cc ~50 minutes 800 mosm/l 50 grams (100cc) 500cc Sterile Water 2cc ~100 minutes 900 mosm/l 75 grams (150cc) 1000cc Sterile Water 2cc ~150 minutes 703 mosm/l 100 grams (200cc) 1000cc Sterile Water 2cc ~200 minutes 893 mosm/l The Riordan IVC Protocol dosing schedule depicted above has served as a safe start for cancer patients new to IVC. The Center for the Improvement of Human Functioning International in Wichita, Kansas, since 1990, has administered over 30,000 onsite IVC infusions according to this protocol. Zero fatalities and rare side effects a testament to its remarkable safety.

32 Effects of High Dose Intravenous Vitamin C Therapy on Health-related Quality of Life in Cancer Patients. Previous anticancer therapy Surgery 8 Chemotherapy (CTx) 20 Radiotherapy (RTx) 1 Surgery+CTX 18 CTx+RTx 3 Surgery + CTx+RTx 1 No standard therapy 9 Total 60 32

33 Results Global Health & QOL Before IVC 2 wks 4 wks * ** * p<0.05 from before IVC. ** p<0.01 from before IVC. (Wilcoxon signed ranks test) 33

34 Functional scale Functional scales Before 2 wks 4 wks Physical * * Role * ** Emotional * ** Cognitive ** Social * ** Values are mean+sd. *p<0.05 and ** p<0.01 from before IVC. (Wilcoxon signed ranks test) 34

35 Symptom scale Symptom scales Before 2 wks 4 wks Fatigue ** ** Insomnia * ** Pain * Constipation * * Financial difficulties * Dyspnea Appetite loss Nausea/vomiting Diarrhea

36 Physician s evaluation 47% 60% Physician s report 2 wks 4 wks Markedly improved 1 ( 2%) 1 ( 2%) Moderately improved 5 ( 8%) 6 (10%) Mildly improved 22 (37%) 29 (48%) Unchanged 30 (50%) 21 (35%) Mildly worsened 2 ( 3%) 3 ( 5%) Moderately worsened 0 ( 0%) 0 ( 0%) Markedly worsened 0 ( 0%) 0 ( 0%) 36

37 Conclusions 1 The effects of high-dose IVC on QOL in 60 cancer patients were studied using EORTIC QLQ-30 assessment. 2 In the global health/quality of life scale, health score improved from 45±28 to 61±24 at 4 weeks after IVC (p<0.01). 3 In functional scale, the patients reported significantly higher scores for physical, role, emotional, cognitive, and social function after IVC (p<0.05). 37

38 Conclusions 4 In symptom scale, patients reported signifcantly lower scores for fatigue, pain, insomnia, constipation and financial difficulties after administration of vitamin C (p<0.05). 5 Physicians reported that 60% of their patients improved QOL after IVC, while 35% was unchanged, and 5% worsened. 6 IVC can be considered as a safe and effective therapy to improve QOL in cancer patients. 38

39 From the 2016 survey of 339 doctors in Japan 39

40 Purpose of the study Most of patients who are diagnosed with cancer must choose from limited options of standard therapy suggested by their oncologist. Among standard therapy options, chemotherapy has strong adverse reactions and drastically lowers QOL. Sometimes it is difficult for the patients to make decisions because chemotherapy often fails to improve conditions, or cancer can recur even if the treatment works. Therefore, we conducted a survey on doctors, who have rich knowledge of medicine, about choices they would make if they were diagnosed cancer. 40

41 Methods (1) We sent an to 650 members of The Japanese College of Intra-venous Therapy (JCIT) and ask to fill out a questionnaire built on the web. (2) We also ask to JCIT members to look for non-member fellows of physician/dentist who replied the same questionnaires on the web. 41